Skip to content
Firazyr(icatibant)
Firazyr (icatibant) is a protein pharmaceutical. Icatibant was first approved as Firazyr on 2008-07-11. It is used to treat hereditary angioedemas in the USA. It has been approved in Europe to treat hereditary angioedemas. The pharmaceutical is active against B2 bradykinin receptor. In addition, it is known to target B1 bradykinin receptor.
Download report
Favorite
COVID-19
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
immune system diseasesD007154
Trade Name
FDA
EMA
Firazyr (generic drugs available since 2019-07-15)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Icatibant acetate
Tradename
Company
Number
Date
Products
FIRAZYRTakedaN-022150 RX2011-08-25
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
firazyrNew Drug Application2020-09-08
icatibantANDA2022-10-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hereditary angioedemasEFO_0004131D054179
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
B: Blood and blood forming organ drugs
B06: Other hematological agents in atc
B06A: Other hematological agents in atc
B06AC: Drugs used in hereditary angioedema
B06AC02: Icatibant
HCPCS
Code
Description
J1744
Injection, icatibant, 1 mg
Clinical
Clinical Trials
26 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hereditary angioedemasD054179EFO_000413115129
Heart failureD006333EFO_0003144I50112
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AngioedemaD000799EFO_0005532T78.31124
Covid-19D000086382U07.1313
Cardiopulmonary bypassD002315111
InflammationD007249111
FibrinolysisD005342111
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Mitochondrial diseasesD028361EFO_000059111
Joint diseasesD007592HP_0003040M12.911
PneumoniaD011014EFO_0003106J1811
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myocardial ischemiaD017202EFO_1001375I20-I2522
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameICATIBANT
INNicatibant
Description
ICATIBANT
Classification
Protein
Drug classantiasthmatics (bradykinin antagonists)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
N=C(N)NCCC[C@H](NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2N1C(=O)[C@H]1Cc2ccccc2CN1C(=O)[C@H](CO)NC(=O)[C@H](Cc1cccs1)NC(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](N)CCCNC(=N)N)C(=O)O
Identifiers
PDB
CAS-ID130308-48-4
RxCUI1148138
ChEMBL IDCHEMBL2028850
ChEBI ID
PubChem CID6918173
DrugBankDB06196
UNII ID7PG89G35Q7 (ChemIDplus, GSRS)
Target
Agency Approved
BDKRB2
BDKRB2
Organism
Homo sapiens
Gene name
BDKRB2
Gene synonyms
BKR2
NCBI Gene ID
Protein name
B2 bradykinin receptor
Protein synonyms
BK-2 receptor
Uniprot ID
Mouse ortholog
Bdkrb2 (12062)
B2 bradykinin receptor (P32299)
Alternate
BDKRB1
BDKRB1
Organism
Homo sapiens
Gene name
BDKRB1
Gene synonyms
BRADYB1
NCBI Gene ID
Protein name
B1 bradykinin receptor
Protein synonyms
BK-1 receptor, bradykinin B1 receptor, bradykinin receptor 1
Uniprot ID
Mouse ortholog
Bdkrb1 (12061)
B1 bradykinin receptor (Q9Z1F4)
Variants
Clinical Variant
No data
Financial
Firazyr - Takeda
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Firazyr - Shire
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,321 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
205 adverse events reported
View more details